Taysha Gene Therapies (NASDAQ:TSHA) Posts Earnings Results, Beats Estimates By $0.01 EPS

Taysha Gene Therapies (NASDAQ:TSHA) released its quarterly earnings results on Monday. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.01, Zacks reports. Taysha Gene Therapies had a negative return on equity of 782.81% and a negative net margin of 833.60%. The business had revenue of $1.11 million during the quarter, compared to the consensus estimate of $3.62 million. During the same period in the previous year, the company posted ($0.38) EPS.

Taysha Gene Therapies Stock Performance

Shares of NASDAQ:TSHA traded down $0.08 during trading on Wednesday, hitting $2.20. The company’s stock had a trading volume of 307,725 shares, compared to its average volume of 2,508,608. The company has a debt-to-equity ratio of 0.75, a current ratio of 3.38 and a quick ratio of 3.38. The firm has a market cap of $411.44 million, a price-to-earnings ratio of -4.65 and a beta of 0.41. The company has a 50-day moving average of $2.59 and a 200-day moving average of $2.56. Taysha Gene Therapies has a 12 month low of $1.27 and a 12 month high of $4.32.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on TSHA. Chardan Capital reiterated a “buy” rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a research report on Tuesday. Needham & Company LLC cut their target price on Taysha Gene Therapies from $7.00 to $6.00 and set a “buy” rating for the company in a research report on Monday. JMP Securities restated a “market outperform” rating and issued a $5.00 price target on shares of Taysha Gene Therapies in a research report on Thursday, June 20th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $8.00 price target (up previously from $2.00) on shares of Taysha Gene Therapies in a research note on Tuesday, May 14th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a research note on Thursday, June 20th. Ten equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $6.40.

Insider Buying and Selling at Taysha Gene Therapies

In related news, major shareholder Paul B. Manning bought 1,333,333 shares of the firm’s stock in a transaction that occurred on Thursday, June 27th. The shares were bought at an average cost of $2.25 per share, with a total value of $2,999,999.25. Following the acquisition, the insider now owns 1,333,333 shares in the company, valued at $2,999,999.25. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 2.70% of the stock is owned by corporate insiders.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.